No hay productos en el carrito



Tumors of the Central Nervous System, Vol. 2: Gliomas: Glioblastoma (Part 2)
Hayat, M.
1ª Edición Abril 2011
Inglés
Tapa dura
980 pags
2800 gr
null x null x null cm
ISBN 9789400706170
Editorial SPRINGER
LIBRO IMPRESO
-5%
207,99 €197,59 €IVA incluido
199,99 €189,99 €IVA no incluido
Recíbelo en un plazo de
2 - 3 semanas
Advantages and limitations of biomarkers in gliomagenesis are described. Molecular subtypes of gliomas are detailed. The role played by TP53 gene mutation in the deadliest brain tumor, glioblastoma multiforme, is pointed out. The role of mutations of IDH1 and IDH2, and isocitrate dehydrogenases in malignant gliomas are presented. Metabolic differences in different regions of the glioma tumor are clarified. Various types of imaging modalities, including PET and SPECT, to diagnose gliomas in general and glioblastoma in particular in patients are explained in detail. Both low-grade and high-grade gliomas are discussed. Conventional as well as fluorescent-guided resection techniques for high-grade, recurrent malignant gliomas are detailed. Impact of resection extent on outcomes in patients with high-grade gliomas is clarified. The advantage of the use of intraoperative low-field MRI in glioma surgery is explained.
Content Level » Professional/practitioner
Keywords » Chemotherapy - Diagnosis of brain tumors - Glioblastoma multiforme - Radiotherapy - Treatment of brain tumors
Related subjects » Cancer Research - Oncology & Hematology - Pathology - Radiology - Surgery
Table of contents
Chapter 1. INTRODUCTION. I. BIOMARKERS AND DIAGNOSIS. Chapter 2. GLIOMAGENESIS:
ADVANTAGES AND LIMITATIONS OF BIOMARKERS. Chapter 3. MOLECULAR SUBTYPES OF GLIOMAS.
Chapter 4. GLIOBLASTOMA: GERMLINE MUTATION OF TP5. Chapter 5. GLIOMAS: ROLE
OF THE TP53 GENE. Chapter 6. THE ROLE OF IDH1 AND IDH2 MUTATIONS IN MALIGNANT
GLIOMAS. Chapter 7. MALIGNANT GLIOMA: ISOCITRATE DEHYDROGENASES 1 AND 2 MUTATIONS.
Chapter 8. METABOLIC DIFFERNCES IN DIFFERENT REGIONS OF GLIOMA SAMPLES. Chapter
9. GLIOBLASTOMA PATIENTS: ROLE OF METHYLATED MGMT. Chapter 10. BRAIN TUMOR ANGIOGENESIS
AND GLIOMA GRADING: ROLE OF TUMOR BLOOD VOLUME AND PERMEABILITY ESTIMATES USING
PERFUSION CT. Chapter 11. VASCULOGENIC MIMICRY IN GLIOMA. Chapter 12. NEWLY
DIAGNOSED GLIOMA: DIAGNOSIS USING POSITRON EMISSION TOMOGRAPHY WITH METHIONINE
AND FLUOROTHYMIDINE. Chapter 13. ROLE OF DIFFUSION TENSOR IMAGING IN DIFFERENTIATION
OF GLIOBLASTOMAS FROM SOLITARY BRAIN METASTASES. Chapter 14. I-TM-601 SPECT
IMAGING OF HUMAN GLIOMA. Chapter 15. ASSESSMENT OF BIOLOGICAL TARGET VOLUME
USING POSITRON EMISSION TOMOGRAPHY IN HIGH-GRADE GLIOMA PATIENTS. Chapter 16.
SKIN METASTASES OF GLIOBLASTOMA. II. THERAPY. Chapter 17. DIFFUSE LOW-GRADE
GLIOMAS. WHAT DOES “COMPLETE RESECTION” MEAN? Chapter 18. QUANTITATIVE
APPROACH OF THE NATURAL COURSE OF DIFFUSE LOW-GRADE GLIOMAS. Chapter 19. IMPACT
OF RESECTION EXTENT ON OUTCOMES IN PATIENTS WITH HIGH-GRADE GLIOMAS. Chapter
20. RECURRENT MALIGNANT GLIOMAS: 5-AMINOLEVULINIC ACID FLUORESCENCE-GUIDED RESECTION.
Chapter 21. GLIOMA SURGERY: INTRAOPERATIVE LOW FIELD MAGNETIC RESONANCE IMAGING.
Chapter 22. LOW-GRADE GLIOMAS: INTRAOPERATIVE ELECTRICAL STIMULATIONS. Chapter
23. MALIGNANT GLIOMAS: PRESENT AND FUTURE THERAPEUTIC DRUGS. Chapter 24. RECURRENT
MALIGNANT GLIOMA PATIENTS: TREATMENT WITH CONFORMAL RADIOTHERAPY AND SYSTEMIC
THERAPY. Chapter 25. GLIOBLASTOMA: BORON NEUTRON CAPTURE THERAPY. Chapter 26.
GLIOBLASTOMA: ANTI-TUMOR ACTION OF CYCLOSPORINE A AND FUCTIONALLY RELATED DRUGS.Chapter
27. GLIOBLASTOMA PATIENTS: CHEMOTHERAPY WITH CISPLATIN, TEMOZOLOMIDE AND THALIDOMIDE.
Chapter 28. GLIOBLASTOMA : ROLE OF GALECTIN- 1 IN CHEMORESISTANCE. Chapter 29.
GLIOMA-INITIATING CELLS: INTERFERON TREATMENT. Chapter 30. GLIOBLASTOMA : ANTITUMOR
ACTION OF NATURAL AND SYNTHETIC CANNABINOIDS. Chapter 31. PATIENTS WITH RECURRENT
HIGH-GRADE GLIOMA: THERAPY WITH COMBINATION OF BEVACIZUMAB AND IRINOTECAN. Chapter
32. MONITORING GLIOMAS IN VIVO USING DIFFUSION- WEIGHTED MRI DURING GENE THREAPY
–INDUCED APOPTOSIS. Chapter 33. HIGH-GRADE GLIOMAS: DENDRITIC CELL THERAPY.
Chapter 34. GLIOBLASTOMA MULTIFORME: USE OF ADENOVIRAL VECTORS. Chapter 35.
FISCHER-F98 GLIOMA MODEL: METHODOLOGY. Chapter 36. CELLULAR CHARACTERIZATION
OF ANTI-VEGF AND IL-6 THERAPY IN EXPERIMENTAL GLIOMA. Chapter 37. ADULT BRAINSTEM
GLIOMAS: DIAGNOSIS AND TREATMENT . Chapter 38. USE OF LOW MOLECULAR WEIGHT HEPARIN
IN THE TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASE IN GLIOMA PATIENTS.
III. PROGNOSIS. Chapter 39. BRAINSTEM GLIOMAS: AN OVERVIEW. Chapter 40. TUMOR-ASSOCIATED
EPILEPSY IN PATIENTS WITH GLIOMA. Chapter 41. CHRONIC EPILEPSY ASSOCIATED WITH
BRAIN TUMORS: SURGICAL NEUROPATHOLOGY. Chapter 42. LOW-GRADE GLIOMAS: ROLE OF
RELATIVE CEREBRAL BLOOD VOLUME IN MALIGNANT TRANSFORMATION. Chapter 43. ANGIOCENTRIC
GLIOMA- INDUCED SEIZURES: LESIONECTOMY.
© 2025 Axón Librería S.L.
2.149.0